FGFR2 (C491S/V564L)
Sign in to save this workspaceFGFR2 · Variant type: compound · HGVS: p.C491S;p.V564L
Components
p.C491Sp.V564L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 100.0% | 0.0% | 93.69 |
| 2 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 3 | Fedratinib | 96.6% | 3.4% | 96.21 |
| 4 | Sunitinib | 96.2% | 3.8% | 91.73 |
| 5 | Repotrectinib | 95.8% | 4.2% | 84.21 |
| 6 | Selpercatinib | 94.6% | 5.4% | 96.72 |
| 7 | Defactinib | 94.2% | 5.8% | 92.68 |
| 8 | Erdafitinib | 86.7% | 13.3% | 95.71 |
| 9 | Pacritinib | 81.1% | 18.9% | 88.64 |
| 10 | Pemigatinib | 76.5% | 23.5% | 98.23 |
| 11 | Alpelisib | 72.2% | 27.8% | 97.22 |
| 12 | Pexidartinib | 69.4% | 30.6% | 99.49 |
| 13 | Upadacitinib | 66.1% | 33.9% | 97.98 |
| 14 | Avapritinib | 66.1% | 33.9% | 97.73 |
| 15 | Tivozanib | 59.7% | 40.3% | 92.42 |
| 16 | Gilteritinib | 56.8% | 43.2% | 88.97 |
| 17 | Tenalisib | 47.6% | 52.4% | 97.98 |
| 18 | Infigratinib | 29.3% | 70.7% | 98.24 |
| 19 | Deucravacitinib | 29.0% | 71.0% | 98.99 |
| 20 | Darovasertib | 28.2% | 71.8% | 96.99 |
| 21 | Neratinib | 21.5% | 78.5% | 93.18 |
| 22 | Rabusertib | 19.8% | 80.2% | 98.74 |
| 23 | Futibatinib | 18.2% | 81.8% | 98.48 |
| 24 | Ripretinib | 14.1% | 85.9% | 92.95 |
| 25 | Sorafenib | 12.9% | 87.1% | 96.72 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 100.0% | 81.5% | +18.5% |
| Pralsetinib | 100.0% | 93.2% | +6.8% |
| Fedratinib | 96.6% | — | — |
| Sunitinib | 96.2% | — | — |
| Repotrectinib | 95.8% | 79.8% | +16.0% |
| Selpercatinib | 94.6% | 95.0% | -0.4% |
| Defactinib | 94.2% | — | — |
| Erdafitinib | 86.7% | 99.0% | -12.3% |
| Pacritinib | 81.1% | — | — |
| Pemigatinib | 76.5% | 98.7% | -22.2% |
| Alpelisib | 72.2% | 98.9% | -26.7% |
| Pexidartinib | 69.4% | — | — |
| Upadacitinib | 66.1% | — | — |
| Avapritinib | 66.1% | — | — |
| Tivozanib | 59.7% | — | — |
| Gilteritinib | 56.8% | — | — |
| Tenalisib | 47.6% | 96.0% | -48.4% |
| Infigratinib | 29.3% | 98.8% | -69.5% |
| Deucravacitinib | 29.0% | 92.5% | -63.5% |
| Darovasertib | 28.2% | — | — |
| Neratinib | 21.5% | — | — |
| Rabusertib | 19.8% | — | — |
| Futibatinib | 18.2% | 99.3% | -81.1% |
| Ripretinib | 14.1% | 85.4% | -71.2% |
| Sorafenib | 12.9% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.6ms